| Health / Medical Topics |
HLA-A*2402-restricted CDCA1-A24-56 Peptide Vaccine
A cancer vaccine containing the HLA-A*2402-restricted peptide epitope derived from cell division associated gene 1 (CDCA1), with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*2402-restricted CDCA1-A24-56 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CDCA1-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from:…
A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor…
A cancer vaccine containing three HLA-A*0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the…
A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor…
A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT),…
Human HLA-A wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes…
